SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong1/28/2025 3:42:53 PM
1 Recommendation

Recommended By
Return to Sender

   of 7980
 
Novo Nordisk's Ozempic gets FDA approval for kidney disease

Jan. 28, 2025 3:15 PM ET
By: Val Brickates Kennedy, SA News Editor

hapabapa

Novo Nordisk ( NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

The Danish drugmaker said the approval makes semaglutide the first GLP-1 RA drug approved for the indication. Semaglutide is also approved for weight loss and is marketed for that indication under the name Wegovy.

In 2020, Ozempic was granted additional approval to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's ( LLY) tirzepatide, which is marketed for diabetes as Mounjaro and for weight loss as Zepbound.

Other companies working on GLP-1 drugs include AstraZeneca ( AZN), Amgen ( AMGN), Pfizer ( PFE), Roche ( OTCQX:RHHBY), Altimmune ( ALT), Viking Therapeutics ( VKTX), Zealand Pharma ( OTCPK:ZLDPF), Terns Pharmaceuticals ( TERN) and Structure Therapeutics ( GPCR).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News